Page last updated: 2024-11-04

cyclothiazide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cyclothiazide is a thiazide diuretic that was first synthesized in the 1950s. It is a potent diuretic that is used to treat edema, hypertension, and premenstrual syndrome. Cyclothiazide is a white crystalline powder that is soluble in water and alcohol. It is typically administered orally, although it can also be given intravenously. Cyclothiazide acts on the kidneys to increase the excretion of sodium, chloride, and water. It also has a vasodilating effect, which helps to lower blood pressure. Cyclothiazide is effective in treating edema associated with heart failure, cirrhosis, and nephrotic syndrome. It is also used to treat hypertension, although it is not as commonly used as other thiazide diuretics. Cyclothiazide has also been shown to have anti-inflammatory and anti-cancer effects. Cyclothiazide is a safe and effective drug when used as directed. However, it can cause side effects such as dizziness, lightheadedness, headache, and muscle cramps. It can also interact with other drugs, so it is important to talk to your doctor before taking cyclothiazide. The compound has been studied in the past, but is not commonly used today. '

cyclothiazide: inhibits the desensitization of AMPA-type receptors; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cyclothiazide : 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted at positions 3, 5 and 6 by a 2-norbornen-5-yl group, chlorine, and a sulfonamide group, respectively. A thiazide diuretic, it has been used in the management of hypertension and oedema. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2910
CHEMBL ID61593
CHEBI ID31448
SCHEMBL ID121096
MeSH IDM0045761

Synonyms (146)

Synonym
MLS001077326
smr000653479
HMS3266L17
BRD-A38675539-001-01-0
2h-1,2,4-benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide
KBIO1_000904
DIVK1C_000904
3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
EU-0100321
lilly 35,483
c14h16cln3o4s2
2h-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide
anhydron
valmiran
ciclotiazida [inn-spanish]
2h-1,2,4-benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide
mdi 193
2h-1,2,4-benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide
aquirel
fluidil
6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
cyclothiazidum [inn-latin]
hsdb 3310
ciclotiazide [dcit]
einecs 218-859-7
brn 0722843
2h-1,2,4-benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide
doburil
renazide
3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
cyclothiazide
2259-96-3
SPECTRUM5_001639
BPBIO1_001320
IDI1_000904
BIOMOL-NT_000224
LOPAC0_000321
6-chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DB00606
6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide
6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
D01256
cyclothiazide (jan/usan/inn)
anhydron (tn)
NCGC00024745-04
KBIOGR_000519
NINDS_000904
SPECTRUM4_000050
NCGC00024745-03
NCGC00024745-02
NCGC00015288-04
6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2h-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide
C 9847 ,
HMS2093A19
3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide(clothiazide)
bdbm50192229
6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2h-1,2,4-benzothiazidiazine-7-sulfonamide-1,1-dioxide
3-bicyclo[2.2.1]hept-5-en-2-yl-7-chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lambda*6*-benzo[1,2,4]thiadiazine-6-sulfonic acid amide
NCGC00015288-07
nsc-758431
CHEMBL61593 ,
CHEBI:31448 ,
ciclotiazida
cyclothiazidum
3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
HMS502N06
FT-0665417
NCGC00015288-06
NCGC00022985-02
HMS3261A03
cyclothiazide [usan:usp:inn:ban]
p71u09g5bw ,
ciclotiazide
nsc 758431
unii-p71u09g5bw
pharmakon1600-01503263
nsc758431
dtxsid3022871 ,
dtxcid302871
cas-2259-96-3
tox21_110124
CCG-204416
HMS2236K04
NCGC00015288-05
LP00321
S6611
3-{bicyclo[2.2.1]hept-5-en-2-yl}-6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide
gtpl4167
HMS3373E04
SCHEMBL121096
tox21_110124_1
NCGC00015288-09
cyclothiazide [usan]
cyclothiazide [who-dd]
cyclothiazide [inn]
cyclothiazide [vandf]
cyclothiazide [mart.]
cyclothiazide [mi]
cyclothiazide [usp-rs]
cyclothiazide [orange book]
cyclothiazide [jan]
cyclothiazide [hsdb]
3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide #
lilly 35483
NCGC00261006-01
tox21_500321
HB0221
6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2h-1,2,4-benzothiazidiazine-7-sulfonamide-1 ,1-dioxide
AKOS024458615
AB00053281_04
SR-01000075796-1
sr-01000075796
J-014778
SR-01000075796-4
SR-01000075796-3
SBI-0050309.P003
Q5199066
HMS3675D03
disodiumhexafluorozirconate
C3392
HMS3411D03
BRD-A38675539-001-05-1
3-(2-bicyclo[2.2.1]hept-5-enyl)-6-chloro-1,1-dioxo-3,4-dihydro-2h-1lambda6,2,4-benzothiadiazine-7-sulfonamide
SDCCGSBI-0050309.P004
NCGC00015288-14
lilly 35483; mdi 193; renazide; valmiran
D81850
3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2h-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide
6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2h-1,2-4-benzothiadiazine-7-sulfonamide1,1-dioxide
EN300-18472036
3-{bicyclo[2.2.1]hept-5-en-2-yl}-6-chloro-1,1-dioxo-3,4-dihydro-2h-1lambda6,2,4-benzothiadiazine-7-sulfonamide
AS-76539
2h-1,2,4-benzothiadiazine-7-sulfonamide,3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide
HY-101165
CS-0020935
6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2h-1,2,4-benz othiadiazine-7-sulfonamide 1,1-dioxide
3-bicyclo
cyclothiazidum (inn-latin)
ciclotiazida (inn-spanish)
cyclothiazide (usan:usp:inn:ban)
cyclothiazide (mart.)
cyclothiazide (usp-rs)
3-(bicyclo(2.2.1)hept-5-en-2-yl)-6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
c03aa09

Research Excerpts

Overview

Cyclothiazide (CTZ) is a potent blocker of AMPA receptor desensitization.

ExcerptReferenceRelevance
"Cyclothiazide (CTZ) is a potent blocker of AMPA receptor desensitization. "( Cyclothiazide induces robust epileptiform activity in rat hippocampal neurons both in vitro and in vivo.
Chen, G; Jiang, M; Qi, J; Wang, Y; Warren, P, 2006
)
3.22

Effects

Cyclothiazide has been shown to block desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-preferring receptors and to enhance quisqualate-, AMPA- and kainate-induced neurotoxicity.

ExcerptReferenceRelevance
"Cyclothiazide (CTZ) has been reported to simultaneously enhance glutamate receptor excitation and inhibit GABAA receptor inhibition, and in turn it evokes epileptiform activities in hippocampal neurons. "( Downregulated GABA and BDNF-TrkB pathway in chronic cyclothiazide seizure model.
Cheng, Z; Kong, S; Liu, J; Wang, Y, 2014
)
2.1
"Cyclothiazide has been shown to block desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-preferring receptors and to enhance quisqualate-, AMPA- and kainate-induced neurotoxicity. "( Characterization of cyclothiazide-enhanced kainate excitotoxicity in rat hippocampal cultures.
Matsumoto, N; Ohno, K; Okada, M; Tsutsumi, R; Yamaguchi, T, 1998
)
2.07

Actions

ExcerptReferenceRelevance
"Cyclothiazide tended to cause hypokalaemia, apparently due to increased potassium loss, but with the present dosage none of the 13 patients developed marked hypokalaemia (serum potassium less than 3.3 mmol/l)."( Antihypertensive, saluretic and hypokalaemic effects of cyclothiazide in comparison with hydrochlorthiazide with amiloride supplement.
Salonen, JT; Ylitalo, P, 1982
)
1.23

Treatment

ExcerptReferenceRelevance
"Cyclothiazide-treated cultures were now vulnerable to AMPA as well as KA; moreover, AMPA was unable to block KA toxicity completely, suggesting that cyclothiazide impaired AMPA/KA receptor desensitization."( Cyclothiazide treatment unmasks AMPA excitotoxicity in rat primary hippocampal cultures.
May, PC; Robison, PM, 1993
)
2.45

Toxicity

ExcerptReferenceRelevance
"Glutamate (Glu), the major excitatory neurotransmitter in the nervous system, is toxic to neurons when it accumulates at high concentrations in the extracellular space."( Rapid desensitization determines the pharmacology of glutamate neurotoxicity.
Moudy, AM; Rothman, SM; Yamada, KA, 1994
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
" It is concluded that in a clinical daily practice of a hypertension clinic low doses of spironolactone or of thiazides combined with potassium-sparing agents reduced BP without alteration in lipid or carbohydrate metabolism on long-term follow-up."( Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension.
Charru, A; Chatellier, G; Corvol, P; Degoulet, P; Jeunemaitre, X; Julien, J; Ménard, J; Plouin, PF, 1988
)
0.27

Bioavailability

ExcerptReferenceRelevance
" Rather, measurement of mEPSCs along with mass spectrometric analysis of CTZ-treated slices indicates that the cause is prolonged bioavailability of CTZ."( Cyclothiazide-induced persistent increase in respiratory-related activity in vitro.
Babiec, WE; Faull, KF; Feldman, JL, 2012
)
1.82
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Cyclothiazide increased the maximum response to a saturating concentration of kainate by approximately 300% and produced a shift to the left. The dose-response curve to glutamate was significantly broader in the presence of the desensitization inhibitor.

ExcerptRelevanceReference
" Cyclothiazide increased the maximum response to a saturating concentration of kainate by approximately 300% and produced a shift to the left in the kainate dose-response curve."( Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate.
Mayer, ML; Patneau, DK; Vyklicky, L, 1993
)
1.49
" The ACh dose-response curve yielded an estimated EC50 of 60 microM."( Inhibition by cyclothiazide of neuronal nicotinic responses in bovine chromaffin cells.
Feltz, A; Nooney, JM, 1995
)
0.65
" In the presence of 300 microM cyclothiazide a 6-fold leftward shift in the kainate dose-response curve for GluR-Aflip but not GluR-Aflop additionally contributes to a difference in potentiation for these splice variants."( Cyclothiazide differentially modulates desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor splice variants.
Mayer, ML; Partin, KM; Patneau, DK, 1994
)
2.02
" The corresponding dose-response curve revealed a half-maximum of current activation at 350 microM."( Glial cells in the mouse hippocampus express AMPA receptors with an intermediate Ca2+ permeability.
Seifert, G; Steinhäuser, C, 1995
)
0.29
" The dose-response relations for the steady-state current evoked by glutamate acting at AMPA receptors in excised outside-out patches from UBC and granule somatic membranes was biphasic, peaking at 50 microM and declining to 50-70% of this value at 1 mM glutamate."( Prolonged physiological entrapment of glutamate in the synaptic cleft of cerebellar unipolar brush cells.
Kinney, GA; Overstreet, LS; Slater, NT, 1997
)
0.3
" YM90K induced a parallel and rightward shift of both kainate and AMPA dose-response curves."( The AMPA-receptor antagonist YM90K reduces AMPA receptor-mediated excitotoxicity in rat hippocampal cultures.
Ohno, K; Okada, M; Sakamoto, S; Tsutsumi, R; Yamaguchi, T, 1998
)
0.3
" Cyclothiazide produced a leftward shift of the kainate dose-response curve and enhanced the maximum response of kainate excitotoxicity."( Characterization of cyclothiazide-enhanced kainate excitotoxicity in rat hippocampal cultures.
Matsumoto, N; Ohno, K; Okada, M; Tsutsumi, R; Yamaguchi, T, 1998
)
1.53
" Furthermore, cyclothiazide shifted the dose-response relationship of the equilibrium current to the right, but slightly suppressed the kainate-induced sustained current."( Modulation of desensitization at glutamate receptors in isolated crucian carp horizontal cells by concanavalin A, cyclothiazide, aniracetam and PEPA.
Lu, T; Shen, Y; Yang, XL, 1999
)
0.87
" By comparing the increase in amplitude of the AMPA receptor response in the Bergmann glia (840 +/- 240%; n = 8) with the shift in the glutamate dose-response curve measured in excised patches (EC50, 1810 microM in control vs 304 microM in CTZ), we estimate that the extrasynaptic transmitter concentration reaches 160-190 microM."( The concentration of synaptically released glutamate outside of the climbing fiber-Purkinje cell synaptic cleft.
Dzubay, JA; Jahr, CE, 1999
)
0.3
" Surprisingly, the dose-response relationship between [Ca(2+)](i) and release rate was shifted slightly to the right in more mature calyces, rendering their vesicles slightly less sensitive to incoming Ca(2+)."( Synaptic vesicles in mature calyx of Held synapses sense higher nanodomain calcium concentrations during action potential-evoked glutamate release.
Neher, E; Taschenberger, H; Wang, LY, 2008
)
0.35
" The dose-response curve to glutamate was significantly broader in the presence of the desensitization inhibitor cyclothiazide."( Pharmacological characterization, localization, and regulation of ionotropic glutamate receptors in skate horizontal cells.
Birnbaum, AD; Kreitzer, MA; Malchow, RP; Qian, H,
)
0.34
" The dose-response analyses revealed dual effects of NS1376."( A novel dualistic profile of an allosteric AMPA receptor modulator identified through studies on recombinant receptors, mouse hippocampal synapses and crystal structures.
Christiansen, GB; Egebjerg, J; Frydenvang, K; Gouliaev, AH; Harbak, B; Hede, SE; Holm, MM; Kastrup, JS; Olsen, L, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
diureticAn agent that promotes the excretion of urine through its effects on kidney function.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzothiadiazineHeterocyclic compound of a ring with sulfur and two nitrogen atoms fused to a benzene ring. Members inhibit sodium-potassium-chloride symporters and are used as diuretics.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Cyclothiazide Action Pathway319

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency11.22020.125919.1169125.8920AID2353
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
regulator of G-protein signaling 4Homo sapiens (human)Potency0.37650.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency10.96400.01237.983543.2770AID1645841
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.49150.001530.607315,848.9004AID1224821
GVesicular stomatitis virusPotency13.80290.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency27.54040.00108.379861.1304AID1645840
arylsulfatase AHomo sapiens (human)Potency0.03381.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.60460.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency70.79460.540617.639296.1227AID2364; AID2528
D(1A) dopamine receptorHomo sapiens (human)Potency6.51270.02245.944922.3872AID488982
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.14130.010039.53711,122.0200AID1479
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency100.00000.010323.856763.0957AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency10.69100.425612.059128.1838AID504536
gemininHomo sapiens (human)Potency1.12160.004611.374133.4983AID624296; AID624297
lamin isoform A-delta10Homo sapiens (human)Potency7.61110.891312.067628.1838AID1459; AID1487
Interferon betaHomo sapiens (human)Potency13.80290.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency13.80290.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.37930.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 2Rattus norvegicus (Norway rat)EC50 (µMol)7.60000.00411.62517.6000AID391457
Glutamate receptor 1Homo sapiens (human)EC50 (µMol)19.23330.38004.113810.0000AID477135; AID477240; AID477241; AID477251; AID477545; AID477546
Glutamate receptor 2Homo sapiens (human)EC50 (µMol)38.48800.15003.05607.6000AID1274725; AID477240; AID477241; AID477252; AID477253
Glutamate receptor 3Homo sapiens (human)EC50 (µMol)13.70001.66004.40677.9000AID477254
Glutamate receptor 4Homo sapiens (human)EC50 (µMol)3.80000.29002.87727.6000AID223222; AID270081
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)EC2x (µMol)1.60001.60001.60001.6000AID92192
Glutamate receptor 1Rattus norvegicus (Norway rat)EC5X (µMol)9.80009.80009.80009.8000AID92196
Glutamate receptor 2Rattus norvegicus (Norway rat)EC2x (µMol)1.60001.60001.60001.6000AID92192
Glutamate receptor 2Rattus norvegicus (Norway rat)EC5X (µMol)9.80009.80009.80009.8000AID92196
Glutamate receptor 3Rattus norvegicus (Norway rat)EC2x (µMol)1.60001.60001.60001.6000AID92192
Glutamate receptor 3Rattus norvegicus (Norway rat)EC5X (µMol)9.80009.80009.80009.8000AID92196
Glutamate receptor 4Rattus norvegicus (Norway rat)EC2x (µMol)1.60001.60001.60001.6000AID92192
Glutamate receptor 4Rattus norvegicus (Norway rat)EC5X (µMol)9.80009.80009.80009.8000AID92196
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (84)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of receptor recyclingGlutamate receptor 1Homo sapiens (human)
signal transductionGlutamate receptor 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor 1Homo sapiens (human)
synapse assemblyGlutamate receptor 1Homo sapiens (human)
long-term memoryGlutamate receptor 1Homo sapiens (human)
response to xenobiotic stimulusGlutamate receptor 1Homo sapiens (human)
response to lithium ionGlutamate receptor 1Homo sapiens (human)
positive regulation of gene expressionGlutamate receptor 1Homo sapiens (human)
neuronal action potentialGlutamate receptor 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor 1Homo sapiens (human)
spinal cord developmentGlutamate receptor 1Homo sapiens (human)
cerebral cortex developmentGlutamate receptor 1Homo sapiens (human)
receptor internalizationGlutamate receptor 1Homo sapiens (human)
response to estradiolGlutamate receptor 1Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 1Homo sapiens (human)
response to cocaineGlutamate receptor 1Homo sapiens (human)
positive regulation of membrane potentialGlutamate receptor 1Homo sapiens (human)
response to arsenic-containing substanceGlutamate receptor 1Homo sapiens (human)
response to electrical stimulusGlutamate receptor 1Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
long-term synaptic potentiationGlutamate receptor 1Homo sapiens (human)
long-term synaptic depressionGlutamate receptor 1Homo sapiens (human)
response to fungicideGlutamate receptor 1Homo sapiens (human)
cellular response to amino acid stimulusGlutamate receptor 1Homo sapiens (human)
cellular response to ammonium ionGlutamate receptor 1Homo sapiens (human)
cellular response to dsRNAGlutamate receptor 1Homo sapiens (human)
cellular response to peptide hormone stimulusGlutamate receptor 1Homo sapiens (human)
cellular response to amine stimulusGlutamate receptor 1Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
regulation of postsynaptic cytosolic calcium ion concentrationGlutamate receptor 1Homo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulusGlutamate receptor 1Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 1Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 1Homo sapiens (human)
signal transductionGlutamate receptor 2Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor 2Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 2Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 2Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 2Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor 2Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 2Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor 3Homo sapiens (human)
calcium-mediated signalingGlutamate receptor 3Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 3Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 3Homo sapiens (human)
protein homotetramerizationGlutamate receptor 3Homo sapiens (human)
protein heterotetramerizationGlutamate receptor 3Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
long-term synaptic potentiationGlutamate receptor 3Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 3Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 3Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor 4Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 4Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processGlutamate receptor 4Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 4Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 4Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 4Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 1Homo sapiens (human)
G-protein alpha-subunit bindingGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 1Homo sapiens (human)
protein bindingGlutamate receptor 1Homo sapiens (human)
glutamate receptor activityGlutamate receptor 1Homo sapiens (human)
adenylate cyclase bindingGlutamate receptor 1Homo sapiens (human)
immunoglobulin bindingGlutamate receptor 1Homo sapiens (human)
protein kinase bindingGlutamate receptor 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor 1Homo sapiens (human)
PDZ domain bindingGlutamate receptor 1Homo sapiens (human)
small GTPase bindingGlutamate receptor 1Homo sapiens (human)
myosin V bindingGlutamate receptor 1Homo sapiens (human)
G-protein beta-subunit bindingGlutamate receptor 1Homo sapiens (human)
beta-2 adrenergic receptor bindingGlutamate receptor 1Homo sapiens (human)
glutamate receptor bindingGlutamate receptor 1Homo sapiens (human)
identical protein bindingGlutamate receptor 1Homo sapiens (human)
protein kinase A bindingGlutamate receptor 1Homo sapiens (human)
scaffold protein bindingGlutamate receptor 1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 2Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 2Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 2Homo sapiens (human)
protein bindingGlutamate receptor 2Homo sapiens (human)
ligand-gated monoatomic cation channel activityGlutamate receptor 2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 3Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 3Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 3Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor 3Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 4Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 4Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 4Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (53)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Homo sapiens (human)
cell-cell junctionGlutamate receptor 1Homo sapiens (human)
cell surfaceGlutamate receptor 1Homo sapiens (human)
ER to Golgi transport vesicle membraneGlutamate receptor 1Homo sapiens (human)
postsynaptic densityGlutamate receptor 1Homo sapiens (human)
dendriteGlutamate receptor 1Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 1Homo sapiens (human)
synaptic vesicle membraneGlutamate receptor 1Homo sapiens (human)
neuromuscular junctionGlutamate receptor 1Homo sapiens (human)
early endosome membraneGlutamate receptor 1Homo sapiens (human)
dendritic spine membraneGlutamate receptor 1Homo sapiens (human)
neuronal cell body membraneGlutamate receptor 1Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneGlutamate receptor 1Homo sapiens (human)
neuronal cell bodyGlutamate receptor 1Homo sapiens (human)
dendritic spineGlutamate receptor 1Homo sapiens (human)
dendritic shaftGlutamate receptor 1Homo sapiens (human)
axonal spineGlutamate receptor 1Homo sapiens (human)
neuron spineGlutamate receptor 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor 1Homo sapiens (human)
presynaptic active zone membraneGlutamate receptor 1Homo sapiens (human)
recycling endosomeGlutamate receptor 1Homo sapiens (human)
recycling endosome membraneGlutamate receptor 1Homo sapiens (human)
excitatory synapseGlutamate receptor 1Homo sapiens (human)
synaptic membraneGlutamate receptor 1Homo sapiens (human)
presynapseGlutamate receptor 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 1Homo sapiens (human)
glutamatergic synapseGlutamate receptor 1Homo sapiens (human)
postsynaptic density, intracellular componentGlutamate receptor 1Homo sapiens (human)
perisynaptic spaceGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Homo sapiens (human)
dendritic spineGlutamate receptor 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Homo sapiens (human)
external side of plasma membraneGlutamate receptor 2Homo sapiens (human)
postsynaptic densityGlutamate receptor 2Homo sapiens (human)
dendriteGlutamate receptor 2Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 2Homo sapiens (human)
asymmetric synapseGlutamate receptor 2Homo sapiens (human)
neuronal cell bodyGlutamate receptor 2Homo sapiens (human)
dendritic spineGlutamate receptor 2Homo sapiens (human)
excitatory synapseGlutamate receptor 2Homo sapiens (human)
postsynapseGlutamate receptor 2Homo sapiens (human)
postsynaptic endocytic zoneGlutamate receptor 2Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 2Homo sapiens (human)
plasma membraneGlutamate receptor 2Homo sapiens (human)
dendritic spineGlutamate receptor 2Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 2Homo sapiens (human)
plasma membraneGlutamate receptor 3Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 3Homo sapiens (human)
postsynaptic membraneGlutamate receptor 3Homo sapiens (human)
parallel fiber to Purkinje cell synapseGlutamate receptor 3Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 3Homo sapiens (human)
plasma membraneGlutamate receptor 3Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 3Homo sapiens (human)
dendritic spineGlutamate receptor 3Homo sapiens (human)
plasma membraneGlutamate receptor 4Homo sapiens (human)
dendriteGlutamate receptor 4Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 4Homo sapiens (human)
neuronal cell bodyGlutamate receptor 4Homo sapiens (human)
dendritic spineGlutamate receptor 4Homo sapiens (human)
extracellular vesicleGlutamate receptor 4Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 4Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 4Homo sapiens (human)
plasma membraneGlutamate receptor 4Homo sapiens (human)
dendritic spineGlutamate receptor 4Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (135)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346557Human GluA1 (Ionotropic glutamate receptors)2001Neuropharmacology, Jun, Volume: 40, Issue:8
Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.
AID1346582Human GluA2 (Ionotropic glutamate receptors)2001Neuropharmacology, Jun, Volume: 40, Issue:8
Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.
AID1346546Human GluA4 (Ionotropic glutamate receptors)2001Neuropharmacology, Jun, Volume: 40, Issue:8
Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.
AID1346589Human GluA3 (Ionotropic glutamate receptors)2001Neuropharmacology, Jun, Volume: 40, Issue:8
Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.
AID345812Potentiation of Wistar rat AMPA receptor expressed in Xenopus laevis oocytes assessed as 5-fold increase in amplitude of (S)-AMPA-induced current by two electrode voltage-clamp method2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of a second generation of pyridothiadiazine 1,1-dioxides acting as AMPA potentiators.
AID92192Concentration of drug giving a 2-fold increase of the magnitude of the current induced by Ionotropic glutamate receptor AMPA (30 uM) and measured in Xenopus Oocytes expressing Rat Cortex AMPA Receptors1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID477549Activity at recombinant GluA3 receptor flip isoform expressed in Xenopus oocytes assessed as potentiation of 10 uM AMPA-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477545Activity at recombinant GluA1 receptor flip isoform expressed in Xenopus oocytes co-expressing gamma2-TARP assessed as effect on 10 uM glutamate-induced current by voltage-clamp electrophysiological assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477235Activity at recombinant GluA3 receptor flip isoform expressed in Xenopus oocytes assessed as potentiation of glutamate-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID415581Agonist activity at AMPA receptor in rat purkinje neurons assessed as potentiation of 4000 uM kainate-induced transmembrane current at 30 uM by patch-clamp technique relative to kainate2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Novel isothiourea derivatives as potent neuroprotectors and cognition enhancers: synthesis, biological and physicochemical properties.
AID477241Activity at recombinant GluA1A2 receptor flop isoform expressed in Xenopus oocytes assessed as effect on 300 uM glutamate-induced current2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477242Activity at recombinant GluA2A4 receptor flip isoform expressed in Xenopus oocytes assessed as effect on 300 uM glutamate-induced current2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID415608Agonist activity at AMPA receptor in rat purkinje neurons assessed as potentiation of 500 uM kainate-induced transmembrane current at 50 uM relative to kainate2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Novel isothiourea derivatives as potent neuroprotectors and cognition enhancers: synthesis, biological and physicochemical properties.
AID477254Activity at human recombinant GluA3 receptor flip isoform expressed in HEK293 cells assessed as effect on glutamate-induced calcium flux by Fluo-4/AM staining-based fluorescence assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477553Activity at recombinant GluA1 receptor flip/GluA2 receptor flop isoform expressed in Xenopus oocytes assessed as potentiation of 10 uM AMPA-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID270081Activity against human GLUR4 flip expressed in HEK293 cells assessed as glutamate-stimulated calcium influx by FLIPR assay2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
A novel class of AMPA receptor allosteric modulators. Part 1: design, synthesis, and SAR of 3-aryl-4-cyano-5-substituted-heteroaryl-2-carboxylic acid derivatives.
AID291179Activity at Wistar rat cortex AMPA receptor expressed in Xenopus laevis oocytes assessed as 5-fold increase of (S)-AMPA-induced current2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design, synthesis, and pharmacology of novel 7-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides as positive allosteric modulators of AMPA receptors.
AID415580Agonist activity at AMPA receptor in rat purkinje neurons assessed as potentiation of 1000 uM kainate-induced transmembrane current at 30 uM by patch-clamp technique relative to kainate2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Novel isothiourea derivatives as potent neuroprotectors and cognition enhancers: synthesis, biological and physicochemical properties.
AID477552Activity at recombinant GluA2A3 receptor flop isoform expressed in Xenopus oocytes assessed as potentiation of 10 uM AMPA-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID1576212Positive allosteric modulation of rat Purkinje neuron AMPA receptor assessed as change in kainate-induced current at 10'-7 M measured for 2 mins by patch clamp assay (rvb = 100%)2019MedChemComm, Sep-01, Volume: 10, Issue:9
Bivalent AMPA receptor positive allosteric modulators of the bis(pyrimidine) series.
AID477548Activity at recombinant GluA1 receptor flop isoform expressed in Xenopus oocytes assessed as potentiation of 10 uM AMPA-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID458611Induction of amplitude current in Xenopus laevis oocytes assessed as 2 fold increase in AMPA-induced current by voltage clamp method2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New fluorinated 1,2,4-benzothiadiazine 1,1-dioxides: discovery of an orally active cognitive enhancer acting through potentiation of the 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors.
AID477243Activity at recombinant GluA2A4 receptor flop isoform expressed in Xenopus oocytes assessed as effect on 300 uM glutamate-induced current2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477237Activity at recombinant GluA1A2 receptor flip isoform expressed in Xenopus oocytes assessed as potentiation of glutamate-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID223222Tested for potentiation towards human iGluR4 receptor expressed in HEK293 cells2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3- (5-methyl-3-hydroxyisoxazol-4-yl)- propanoic acid (AMPA) receptors.
AID602704Positive allosteric modulation at AMPA receptor in Sprague-Dawley rat embryonic hippocampal neuron assessed as concentration required to double the steady-state current induced by glutamate by patch-clamp assay2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Benzoxazinones as potent positive allosteric AMPA receptor modulators: part I.
AID477550Activity at recombinant GluA3 receptor flop isoform expressed in Xenopus oocytes assessed as potentiation of 10 uM AMPA-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477554Activity at recombinant GluA1 receptor flop/GluA2 receptor flip isoform expressed in Xenopus oocytes assessed as potentiation of 10 uM AMPA-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID270083Activity against human GLUR2 flip expressed in HEK293 cells assessed as glutamate-stimulated calcium influx by FLIPR assay2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
A novel class of AMPA receptor allosteric modulators. Part 1: design, synthesis, and SAR of 3-aryl-4-cyano-5-substituted-heteroaryl-2-carboxylic acid derivatives.
AID415579Agonist activity at AMPA receptor in rat purkinje neurons assessed as potentiation of kainate-induced transmembrane current at 30 uM by patch-clamp technique relative to kainate2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Novel isothiourea derivatives as potent neuroprotectors and cognition enhancers: synthesis, biological and physicochemical properties.
AID1388335Antiallodynic activity in Sprague-Dawley rat model of spared nerve injury-induced allodynia assessed as inhibition of electrically evoked inhibitory post-synaptic current amplitude in spinal cord by electrophysiology method2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Modulation of Glycine-Mediated Spinal Neurotransmission for the Treatment of Chronic Pain.
AID477547Activity at recombinant GluA1 receptor flip isoform expressed in Xenopus oocytes assessed as potentiation of 10 uM AMPA-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID345811Potentiation of Wistar rat AMPA receptor expressed in Xenopus laevis oocytes assessed as 2-fold increase in amplitude of (S)-AMPA-induced current by two electrode voltage-clamp method2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of a second generation of pyridothiadiazine 1,1-dioxides acting as AMPA potentiators.
AID477238Activity at recombinant GluA1A2 receptor flop isoform expressed in Xenopus oocytes assessed as potentiation of glutamate-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID146417Variation of kainate-activated (KA) currents in primary cultures of cerebellar granule neurons at 1 mM using patch-clamp technique2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis of 3,4-dihydro-2H-1,2,4-benzo-thiadiazine 1,1-dioxide derivatives as potential allosteric modulators of AMPA/kainate receptors.
AID477159Activity at recombinant GluA1 receptor flop isoform expressed in Xenopus oocytes assessed as potentiation of glutamate-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID415609Agonist activity at AMPA receptor in rat purkinje neurons assessed as potentiation of 500 uM glutamate-induced transmembrane current at 30 uM relative to glutamate2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Novel isothiourea derivatives as potent neuroprotectors and cognition enhancers: synthesis, biological and physicochemical properties.
AID477135Agonist activity at recombinant GluA1 receptor flip isoform expressed in Xenopus oocytes2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID231900Ratio between the D50 value and the A50 value; not determined1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID536780Agonist activity at AMPA receptor in rat cortical neurons assessed as change in increase in AMPA current2010Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20
Positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor.
AID291181Activity at Wistar rat cortex AMPA receptor expressed in Xenopus laevis oocytes assessed as maximum increase of (S)-AMPA-induced current2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design, synthesis, and pharmacology of novel 7-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides as positive allosteric modulators of AMPA receptors.
AID1274725Agonist activity at human GluA2(Q)i expressed in HEK293 cells assessed as enhancement of glutamate-evoked desensitized current by whole cell patch clamp method2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Studies on Aryl-Substituted Phenylalanines: Synthesis, Activity, and Different Binding Modes at AMPA Receptors.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID291178Activity at Wistar rat cortex AMPA receptor expressed in Xenopus laevis oocytes assessed as 2-fold increase of (S)-AMPA-induced current2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design, synthesis, and pharmacology of novel 7-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides as positive allosteric modulators of AMPA receptors.
AID477551Activity at recombinant GluA1A2 receptor flop isoform expressed in Xenopus oocytes assessed as potentiation of 10 uM AMPA-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID175394Effect on duration of the postsynaptic excitatory potentials induced by electric stimulation in rat hippocampal slices1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID92496Inhibition of binding to AMPA receptor from rat cerebral cortex2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
[3H]N-2-(4-(N-benzamido)phenyl)propyl-2-propanesulfonamide: a novel AMPA receptor potentiator and radioligand.
AID1576214Positive allosteric modulation of rat Purkinje neuron AMPA receptor assessed as change in kainate-induced current at 10'-5 M measured for 2 mins by patch clamp assay (rvb = 100%)2019MedChemComm, Sep-01, Volume: 10, Issue:9
Bivalent AMPA receptor positive allosteric modulators of the bis(pyrimidine) series.
AID291180Activity at Wistar rat cortex AMPA receptor expressed in Xenopus laevis oocytes assessed as effect on (S)-AMPA-induced current2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design, synthesis, and pharmacology of novel 7-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides as positive allosteric modulators of AMPA receptors.
AID477255Activity at human recombinant GluA4 receptor flip isoform expressed in HEK293 cells assessed as effect on glutamate-induced calcium flux by Fluo-4/AM staining-based fluorescence assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID391457Agonist activity at rat flip iGluR2(Q) expressed in Xenopus laevis oocytes by whole cell patch-clamp method2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of potent and Selective iGluR5 modulators.
AID458612Induction of membrane depolarization in rat E16 cells assessed as 2 fold increase in AMPA-induced fluorescence by flipR method2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New fluorinated 1,2,4-benzothiadiazine 1,1-dioxides: discovery of an orally active cognitive enhancer acting through potentiation of the 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors.
AID291183Increase in (S)-AMPA-stimulated [3H]noradrenaline release in Wistar rat hippocampus at 30 uM relative to control2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design, synthesis, and pharmacology of novel 7-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides as positive allosteric modulators of AMPA receptors.
AID477239Activity at recombinant GluA4 receptor flip isoform expressed in Xenopus oocytes assessed as effect on 300 uM glutamate-induced current2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID169271Effect on amplitude of the postsynaptic excitatory potentials induced by electric stimulation in rat hippocampal slices1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID459004Binding affinity to subsite B/B' and subsite C/C' in S1S2 domain of GluA2 receptor expressed in Escherichia coli by crystallography2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors.
AID1576213Positive allosteric modulation of rat Purkinje neuron AMPA receptor assessed as change in kainate-induced current at 10'-6 M measured for 2 mins by patch clamp assay (rvb = 100%)2019MedChemComm, Sep-01, Volume: 10, Issue:9
Bivalent AMPA receptor positive allosteric modulators of the bis(pyrimidine) series.
AID477240Activity at recombinant GluA1A2 receptor flip isoform expressed in Xenopus oocytes assessed as effect on 300 uM glutamate-induced current2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477546Activity at recombinant GluA1 receptor flop isoform expressed in Xenopus oocytes co-expressing gamma2-TARP assessed as effect on 10 uM glutamate-induced current by voltage-clamp electrophysiological assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID1576215Positive allosteric modulation of rat Purkinje neuron AMPA receptor assessed as change in kainate-induced current at 3 x 10'-5 M measured for 2 mins by patch clamp assay (rvb = 100%)2019MedChemComm, Sep-01, Volume: 10, Issue:9
Bivalent AMPA receptor positive allosteric modulators of the bis(pyrimidine) series.
AID477110Activity at recombinant GluA1 receptor flip isoform expressed in Xenopus oocytes assessed as potentiation of glutamate-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID345813Potentiation of Wistar rat AMPA receptor expressed in Xenopus laevis oocytes assessed as increase in amplitude of (S)-AMP-induced current by two electrode voltage-clamp method relative to AMPA2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Synthesis and pharmacological evaluation of a second generation of pyridothiadiazine 1,1-dioxides acting as AMPA potentiators.
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID477251Activity at human recombinant GluA1 receptor flip isoform expressed in HEK293 cells assessed as effect on glutamate-induced calcium flux by Fluo-4/AM staining-based fluorescence assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477252Activity at human recombinant GluA2 receptor flip isoform expressed in HEK293 cells assessed as effect on glutamate-induced calcium flux by Fluo-4/AM staining-based fluorescence assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID270082Activity against human GLUR4 flop expressed in HEK293 cells assessed as glutamate-stimulated calcium influx by FLIPR assay2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
A novel class of AMPA receptor allosteric modulators. Part 1: design, synthesis, and SAR of 3-aryl-4-cyano-5-substituted-heteroaryl-2-carboxylic acid derivatives.
AID477253Activity at human recombinant GluA2 receptor flop isoform expressed in HEK293 cells assessed as effect on glutamate-induced calcium flux by Fluo-4/AM staining-based fluorescence assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477556Activity at recombinant GluA2 receptor flip/GluA3 receptor flop isoform expressed in Xenopus oocytes assessed as potentiation of 10 uM AMPA-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID270084Activity against human GLUR2 flop expressed in HEK293 cells assessed as glutamate-stimulated calcium influx by FLIPR assay2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
A novel class of AMPA receptor allosteric modulators. Part 1: design, synthesis, and SAR of 3-aryl-4-cyano-5-substituted-heteroaryl-2-carboxylic acid derivatives.
AID415578Agonist activity at AMPA receptor in rat purkinje neurons assessed as potentiation of glutamate-induced transmembrane current at 30 uM by patch-clamp technique relative to kainate2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Novel isothiourea derivatives as potent neuroprotectors and cognition enhancers: synthesis, biological and physicochemical properties.
AID477236Activity at recombinant GluA4 receptor flip isoform expressed in Xenopus oocytes assessed as potentiation of glutamate-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID477555Activity at recombinant GluA2 receptor flop/GluA3 receptor flip isoform expressed in Xenopus oocytes assessed as potentiation of 10 uM AMPA-induced current at 100 uM relative to control2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.
AID92196concentration of drug giving a 5-fold increase of the magnitude of the current induced by Ionotropic glutamate receptor AMPA (30 uM) and measured in Xenopus Oocytes expressing Rat Cortex AMPA Receptors1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID681388TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (380)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (4.21)18.7374
1990's132 (34.74)18.2507
2000's165 (43.42)29.6817
2010's57 (15.00)24.3611
2020's10 (2.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.54 (24.57)
Research Supply Index5.99 (2.92)
Research Growth Index5.37 (4.65)
Search Engine Demand Index54.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (1.01%)5.53%
Reviews5 (1.26%)6.00%
Case Studies3 (0.76%)4.05%
Observational0 (0.00%)0.25%
Other384 (96.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]